Table 5 Studies reporting any benefit of TTs for osteosarcoma patients

mTOR inhibitors

   Ridaforolimus in patients with advanced bone and soft tissue sarcomas

Chawla et al.

Phase II

2012

   Sirolimus and Cyclophosphamide in patients with advanced sarcomas

Schuetze et al.

Phase II

2012

   Ridaforolimus versus placebo to control metastatic sarcomas in patients after benefit of prior chemotherapy (SUCCEED)

Demetri et al.

Phase III

2013

TKI

   Sorafenib blocks tumour growth, angiogenesis and metastatic potential

Pignochino et al.

preclinical

2009

   Sorafenib in patients with metastatic or recurrent sarcomas

Maki et al.

Phase II

2009

   Sorafenib in relapsed and unresectable high-grade osteosarcoma after failure of tandard multimodal therapy: an Italian Sarcoma Group Study

Grignani et al.

Phase II

2012

   Initial testing of sunitinib by the pediatric preclinical testing program

Maris et al.

Phase I

2008

   Sunitinib in pediatric patients with refractory solid tumors: a Children’s Oncology Group study

Dubois et al.

Phase I

2011

   Sunitinib in patients with relapsed or refractory soft tissue sarcomas

Tariq Mahmood et al.

Phase II

2011

   Pazopanib for metastatic soft-tissue sarcoma (PALETTE)

Van der Graaf et al.

Phase III

2012

   Pazopanib in patients with relapsed or refractory advanced soft-tissue sarcoma

Sleijfer et al.

Phase II

2009